Log in

NASDAQ:OBLNObalon Therapeutics Stock Price, Forecast & News

$0.75
+0.02 (+2.60 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.73
Now: $0.75
$0.76
50-Day Range
$0.68
MA: $0.73
$1.09
52-Week Range
$0.62
Now: $0.75
$3.20
Volume93,710 shs
Average Volume312,891 shs
Market Capitalization$5.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.08
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Read More
Obalon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
CUSIPN/A
Phone844-362-2566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.28 million
Book Value$0.93 per share

Profitability

Net Income$-23,680,000.00
Net Margins-694.12%

Miscellaneous

Employees100
Market Cap$5.79 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$0.75
+0.02 (+2.60 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

How has Obalon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OBLN shares have decreased by 27.9% and is now trading at $0.7495.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Obalon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Obalon Therapeutics
.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Obalon Therapeutics
.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) posted its earnings results on Thursday, July, 30th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.24. The company earned $0.70 million during the quarter. Obalon Therapeutics had a negative net margin of 694.12% and a negative return on equity of 133.43%.
View Obalon Therapeutics' earnings history
.

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Has Obalon Therapeutics been receiving favorable news coverage?

News headlines about OBLN stock have been trending negative on Monday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Obalon Therapeutics
.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the following people:
  • Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
  • Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 57)
  • Ms. Daina Schmidt, VP of Marketing

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $0.75.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $5.79 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is www.obalon.com.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.